Mitomycin (for Bladder Cancer)
Mitomycin is an alkylating antitumor antibiotic. When used for bladder cancer, it is administered directly into the bladder via a catheter (intravesical instillation). This localized delivery maximizes the exposure of the tumor cells to the drug while minimizing systemic side effects.
Dosage by Body Weight
The typical adult dose is 20 mg to 40 mg instilled intravesically once weekly for 6 to 8 weeks. The solution should be retained in the bladder for 1 to 2 hours before voiding. Dosage is not calculated by body weight.
- Body Weight
- Below 5 kg
- Dose
- Not indicated
- Frequency
- Do not use
- Tracking Notes
- Bladder cancer is an adult condition. Intravesical mitomycin is not indicated or established for pediatric use.
- Body Weight
- 5-7 kg
- Dose
- Not indicated
- Frequency
- Do not use
- Tracking Notes
- Bladder cancer is an adult condition. Intravesical mitomycin is not indicated or established for pediatric use.
- Body Weight
- 8-10 kg
- Dose
- Not indicated
- Frequency
- Do not use
- Tracking Notes
- Bladder cancer is an adult condition. Intravesical mitomycin is not indicated or established for pediatric use.
- Body Weight
- 11-15 kg
- Dose
- Not indicated
- Frequency
- Do not use
- Tracking Notes
- Bladder cancer is an adult condition. Intravesical mitomycin is not indicated or established for pediatric use.
- Body Weight
- 16-20 kg
- Dose
- Not indicated
- Frequency
- Do not use
- Tracking Notes
- Bladder cancer is an adult condition. Intravesical mitomycin is not indicated or established for pediatric use.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not indicated | Do not use | Bladder cancer is an adult condition. Intravesical mitomycin is not indicated or established for pediatric use. |
| 5-7 kg | Not indicated | Do not use | Bladder cancer is an adult condition. Intravesical mitomycin is not indicated or established for pediatric use. |
| 8-10 kg | Not indicated | Do not use | Bladder cancer is an adult condition. Intravesical mitomycin is not indicated or established for pediatric use. |
| 11-15 kg | Not indicated | Do not use | Bladder cancer is an adult condition. Intravesical mitomycin is not indicated or established for pediatric use. |
| 16-20 kg | Not indicated | Do not use | Bladder cancer is an adult condition. Intravesical mitomycin is not indicated or established for pediatric use. |
Formulation
Purpose
Used as an intravesical chemotherapeutic agent to treat superficial (non-muscle invasive) bladder cancer and to prevent recurrence after transurethral resection of bladder tumor (TURBT).
Generic Name
Mitomycin-CBranded Drug Names
Mitomycin (for Bladder Cancer) is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.